NBRV - Nabriva Therapeutics EPS beats by $0.06 beats on revenue August, 05 2021 04:16 PM Nabriva Therapeutics plc Nabriva Therapeutics (NASDAQ:NBRV): Q2 GAAP EPS of -$0.29 beats by $0.06. Revenue of $8.24M vs $0.49M in Q220; beats by $2.25M. Press Release For further details see: Nabriva Therapeutics EPS beats by $0.06, beats on revenue